Cargando…
Pancreatic Enzyme Replacement Therapy in Cystic Fibrosis
While typically considered a pulmonary disease, cystic fibrosis patients develop significant nutritional complications and comorbidities, especially those who are pancreatic insufficient. Clinicians must have a high suspicion for cystic fibrosis among patients with clinical symptoms of pancreatic in...
Autores principales: | Freswick, Peter N., Reid, Elizabeth K., Mascarenhas, Maria R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9003370/ https://www.ncbi.nlm.nih.gov/pubmed/35405954 http://dx.doi.org/10.3390/nu14071341 |
Ejemplares similares
-
Acute Pancreatitis in a Previously Exocrine Pancreatic Insufficient Cystic Fibrosis Patient Who Had Improved Pancreatic Function After Being Treated With Lumacaftor/Ivacaftor
por: Redman, Alexander W., et al.
Publicado: (2021) -
Hospitalization rates among patients with cystic fibrosis using pancreatic enzyme replacement therapy
por: Trapnell, Bruce C., et al.
Publicado: (2020) -
Relationship of Initial Pancreatic Enzyme Replacement Therapy Dose With Weight Gain in Infants With Cystic Fibrosis
por: Schechter, Michael S., et al.
Publicado: (2018) -
Correlates of Pancreatic Enzyme Replacement Therapy Intake in Adults with Cystic Fibrosis: Results of a Cross-Sectional Study
por: Olsen, Mette F., et al.
Publicado: (2022) -
Pancreatic Enzyme Replacement Therapy in Pancreatic Cancer
por: Pezzilli, Raffaele, et al.
Publicado: (2020)